Brilinta is manufactured by AstraZeneca [1].
When does Brilinta's patent expire?
The patent for Brilinta (ticagrelor) is complex, involving multiple patents with varying expiration dates. According to DrugPatentWatch.com, the earliest expected patent expiration date for Brilinta in the United States is around October 2023, with later patents extending into 2024 and beyond [2]. However, patent challenges and litigation can influence these dates [2].
How does Brilinta work?
Brilinta is an antiplatelet medication used to prevent blood clots in patients who have had a heart attack or stroke, or who have peripheral arterial disease [3]. It works by inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets [3]. This inhibition prevents ADP from binding to the receptor, thereby reducing platelet activation and aggregation [3].
What are the common side effects of Brilinta?
Common side effects associated with Brilinta include bleeding, shortness of breath, and bruising [4]. More serious side effects can occur, and patients should consult with their healthcare provider if they experience any unusual symptoms [4].
What alternatives are available for Brilinta?
Other antiplatelet medications exist as alternatives to Brilinta, depending on a patient's specific medical condition and history. These may include clopidogrel (Plavix) and prasugrel (Effient), which also target the P2Y12 receptor but have different mechanisms and side effect profiles [5]. The choice of medication is determined by a healthcare professional [5].
Who else is developing generic versions of Brilinta?
Several pharmaceutical companies are developing or have launched generic versions of ticagrelor, the active ingredient in Brilinta. Companies such as Teva Pharmaceuticals, Apotex, and others have been involved in the production of generic ticagrelor [2]. The availability of generics can be influenced by patent litigation outcomes [2].
What is the pricing of Brilinta and its generics?
The price of Brilinta can vary significantly based on insurance coverage, pharmacy, and geographical location. Generic versions of ticagrelor are generally priced lower than the brand-name drug. Information on specific pricing can be obtained from pharmacies or through drug discount programs.
Sources:
[1] https://www.astrazeneca.com/
[2] https://www.drugpatentwatch.com/drug/brilinta
[3] https://www.ncbi.nlm.nih.gov/books/NBK537279/
[4] https://www.webmd.com/drugs/2/drug-76321/brilinta-oral/details
[5] https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.042548